Clinical trial · Interventional
Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women
NCT02440750CI-TRIAL-00021275unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The presence of a thin endometrium has an important role in allowing the best conditions for hysteroscopic surgery. The aim of this study is to evaluate the efficacy of a 21 day administration of 2 mg of dienogest versus ulipristal acetate 5 mg, in rapid endometrial preparation to operative hysteroscopy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Fibroids | Uterine Corpus Leiomyoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dienogest | Drug | — | UNRESOLVED |
| operative hysteroscopy | Procedure | — | UNRESOLVED |
| Ulipristal acetate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Dienogest
- description
- Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
- interventionNames
- Procedure: operative hysteroscopy
- Drug: Dienogest
- type
- EXPERIMENTAL
- label
- Ulipristal acetate
- description
- Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
- interventionNames
- Procedure: operative hysteroscopy
- Drug: Ulipristal acetate
Primary outcomes (1)
- measure
- Endometrial thickness
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis at office hysteroscopy of symptomatic submucous myomas with intramural development (G1 and G2) Exclusion Criteria: * pregnancy * other hormonal therapy in the previous 8 weeks * hepatic or renal impairment * any medical condition that would increase the surgical risk * refusal or unable to sign written consent
References
Publications (0)
Data not yet available
No reference posted for this study.